



## Noxopharm to Present Sofra™ Study at International LUPUS 2023 Conference

- Noxopharm to deliver oral presentation on lupus research at prestigious conference
- Study leverages intellectual property from Sofra™ preclinical platform
- Work conducted with strategic partner Hudson Institute of Medical Research

**Sydney, 22 February 2023:** Innovative biotech company **Noxopharm Limited (ASX:NOX)** announces that research from its inflammation-related Sofra™ preclinical program will be presented orally at the upcoming 15<sup>th</sup> International Congress on Systemic Lupus Erythematosus (LUPUS 2023).

The event will be held in Seoul from 17-20 May and will feature a large audience of more than 2,000 international participants, including world-renowned experts in autoimmune diseases. The abstract will also be published in *Lupus Science & Medicine*®, the official journal of the Lupus Foundation of America.

The abstract has been selected by an expert committee for oral presentation to showcase the results from Noxopharm's proprietary new class of therapeutics, which are demonstrating promising activity against autoimmune diseases such as lupus.

Estimates of the number of individuals suffering from autoimmune diseases in the US alone range from 14 to 24 million cases. In Australia, an estimated 20,000 patients have lupus. Autoimmune diseases are on average two times more prevalent in females than males, while lupus is nine times more prevalent in females. The global immunology market is projected to grow from USD 92 billion in 2021 to USD 158 billion in 2028.

The Sofra™ technology platform is based on in-licensed technology from Melbourne's Hudson Institute of Medical Research via Noxopharm's Pharmorage subsidiary. Unlike other anti-inflammatory drugs that target the end-stages of the inflammatory process, Noxopharm's short nucleic acid sequences, known as oligonucleotides, allow inflammation to be blocked at its source. Sofra™ oligonucleotides have potential applications in the treatment of excessive inflammatory responses, as seen during infections and in autoimmune diseases.

Noxopharm is also actively investigating the potential for its Sofra™ oligonucleotides to limit the inflammatory side effects associated with mRNA therapeutics and vaccines, and exploring related commercial opportunities.

Noxopharm CEO Dr Gisela Mautner said: "To be recognised at such a high-profile conference is a great outcome that reflects the promising nature of the Sofra™ platform. We are working in close collaboration with the Hudson Institute team on these novel therapeutics, and believe that our findings will receive considerable attention from scientists and other biotech companies. There is growing interest in the potential of

oligonucleotides to open up new pathways to treatments for a wide range of diseases, and numerous industry participants are looking to complement or add to their existing portfolios as the technology continues to evolve.”

Hudson Institute A/Prof Michael Gantier said: “We are very pleased to see our work with Noxopharm showcased at this prestigious international conference. Our goal is to progress this research into treating autoimmune diseases at their source, for illnesses that affect millions of people worldwide.”

**-ENDS-**

### **About Noxopharm**

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its lead clinical-stage drug candidate Veyonda<sup>®</sup>, plus two innovative technology platforms Chroma<sup>™</sup> (oncology) and Sofra<sup>™</sup> (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

---

### **About Hudson Institute of Medical Research**

A global bioscience medical research leader, Hudson Institute’s sole focus is on powering breakthrough scientific discoveries into improved health care that will transform lives. We strive to improve human health through ground-breaking, collaborative, medical research discoveries and the translation of these to real world impact.

Hudson Institute scientists research five areas of medical need

- Inflammation
- Reproductive health and pregnancy
- Infant and child health
- Cancer
- Hormones and health

To learn more, please visit: [www.hudson.org.au](http://www.hudson.org.au)

#### **Investor, Corporate & Media enquiries:**

Julian Elliott

M: 0425 840 071

E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

#### **Company Secretary:**

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

**Hudson Institute Media enquiries:**

Rob Clancy

Communications & Media Manager

M: + 61 408 579 313

E: [rob.clancy@hudson.org.au](mailto:rob.clancy@hudson.org.au)

*Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

---

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.